BVF Inc. IL purchased a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,764,471 shares of the company's stock, valued at approximately $19,185,000. Monte Rosa Therapeutics accounts for approximately 0.7% of BVF Inc. IL's portfolio, making the stock its 29th largest holding. BVF Inc. IL owned approximately 4.50% of Monte Rosa Therapeutics at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Monte Rosa Therapeutics by 7.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company's stock worth $49,391,000 after purchasing an additional 515,496 shares in the last quarter. Versant Venture Management LLC acquired a new stake in Monte Rosa Therapeutics during the fourth quarter worth $39,231,000. Vanguard Group Inc. increased its holdings in Monte Rosa Therapeutics by 24.5% in the 4th quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company's stock valued at $21,905,000 after buying an additional 622,134 shares during the period. Geode Capital Management LLC increased its holdings in Monte Rosa Therapeutics by 23.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,044,689 shares of the company's stock valued at $5,538,000 after buying an additional 197,247 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Monte Rosa Therapeutics by 187.3% in the 4th quarter. Marshall Wace LLP now owns 499,492 shares of the company's stock valued at $3,466,000 after buying an additional 325,643 shares in the last quarter. Institutional investors and hedge funds own 79.96% of the company's stock.
Insider Buying and Selling
In related news, Director Chandra P. Leo bought 10,000 shares of the company's stock in a transaction on Monday, March 24th. The stock was bought at an average cost of $5.84 per share, with a total value of $58,400.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $58,400. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.50% of the stock is owned by corporate insiders.
Monte Rosa Therapeutics Price Performance
Shares of NASDAQ:GLUE traded down $0.48 during trading on Tuesday, reaching $4.16. The stock had a trading volume of 330,363 shares, compared to its average volume of 1,053,725. The stock has a market capitalization of $255.57 million, a PE ratio of -2.27 and a beta of 1.52. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.21 and a 52 week high of $12.40. The business's 50-day moving average price is $5.15 and its 200 day moving average price is $6.55.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.60. The business had revenue of $14.00 million during the quarter, compared to the consensus estimate of $43.73 million. Analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.
Analyst Ratings Changes
A number of analysts recently weighed in on GLUE shares. Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 target price on the stock. Wells Fargo & Company lowered their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Friday, March 21st. Finally, Wedbush reiterated an "outperform" rating and set a $17.00 price objective (up from $15.00) on shares of Monte Rosa Therapeutics in a research note on Thursday, March 20th.
Read Our Latest Stock Analysis on GLUE
Monte Rosa Therapeutics Company Profile
(
Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Articles
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
